pharmaceutical investing Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
